Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-14,385
Closed -$161K 330
2023
Q4
$161K Sell
14,385
-6,400
-31% -$58.8K 0.02% 288
2023
Q3
$321K Sell
20,785
-15,300
-42% -$257K 0.05% 230
2023
Q2
$684K Sell
36,085
-150,559
-81% -$2.64M 0.07% 168
2023
Q1
$2.84M Sell
186,644
-8,294
-4% -$108K 0.38% 63
2022
Q4
$2.48M Sell
194,938
-132,398
-40% -$1.19M 0.34% 70
2022
Q3
$1.9M Buy
327,336
+7,881
+2% +$34.6K 0.3% 84
2022
Q2
$1.03M Sell
319,455
-41,405
-11% -$125K 0.15% 142
2022
Q1
$1.36M Buy
360,860
+178,005
+97% +$1.15M 0.17% 131
2021
Q4
$2.39M Sell
182,855
-2,077
-1% -$32.8K 0.32% 86
2021
Q3
$3.62M Sell
184,932
-44,525
-19% -$813K 0.52% 50
2021
Q2
$4.29M Buy
229,457
+46,182
+25% +$1.03M 0.6% 46
2021
Q1
$4.34M Buy
+183,275
New +$4.23M 0.68% 38

Other funds holding ETNB

Pekin Hardy Strauss's ETNB Position: Q1 2024 in Review

Pekin Hardy Strauss sold out of 89bio (ETNB) in Q1 2024, closing a stake of 14,385 shares — an estimated $161K sold.

Pekin Hardy Strauss first reported a position in ETNB in Q1 2021 and held it in 12 quarters. The position peaked at $4.34M in Q1 2021. 150 funds tracked by Wall St. Rank hold ETNB as of Q1 2024.

  • Pekin Hardy Strauss reported no remaining 89bio position as of Q1 2024 after selling out during the quarter.
  • Pekin Hardy Strauss sold 14,385 89bio shares in Q1 2024, an estimated $161K.
  • Pekin Hardy Strauss first reported a position in 89bio in Q1 2021 and held it in 12 quarters.
  • Pekin Hardy Strauss's 89bio position peaked at $4.34M in Q1 2021.
  • 150 funds tracked by Wall St. Rank held 89bio as of Q1 2024.

Based on Pekin Hardy Strauss's 13F filing for Q1 2024, filed 3 May 2024.